About sorafenib in castration-resistant prostate cancer

Annals of Oncology

Volumn 19, Issue 10, 2008, Pages 1812-1813

  Colloca, G ^a   Checcaglini, F ^b   Venturino, A ^a  

^a Ospedale Civile   (Italy)

^b Neurology Unit USL Umbria 1 Città di Castello Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SORAFENIB;

ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; GENE EXPRESSION REGULATION; HORMONE RESPONSE; HORMONE SENSITIVITY; HUMAN; LETTER; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION;

EID: 53049091353     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn546     Document Type: Letter

References (15)

1. Chi KN, Ellard SL, Hotte SJ et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008; 19: 746-751.
2. Dahut WL, Scripture CD, Posadas EM et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2006: 24 (Abstr 4506): 218s.
3. Kelly WK, Scher HI, Mazumdar M et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 607-615.
4. Armstrong AJ, Garrett-Mayer E, Yang YO et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 3965-3970.
5. Petrylak DP, Pauler Ankerst D, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-521.
6. Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007; 13(5): 1488-1492.
7. Small EJ, McMillan A, Meyer M et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival. J Clin Oncol 2001; 19: 1304-1311.
8. Smith DC, Dunn RL, Strawderman MS et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998; 16: 1835-1843.
9. Thuret R, Massard C, Gross-Goupil M et al. The postchemotherapy PSA surge syndrome. Ann Oncol 2008; 19: 1-4.
10. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
11. Dahut WL, Scripture C, Posadas E et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14(1): 209-214.
12. Steinbild S, Mross K, Frost A et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007; 97: 1480-1485.
13. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
14. Jia L, Coetzee GA. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus. Cancer Res 2005; 65(17): 8003-8008.
15. Bakin RE, Gioeli D, Bissonette EA et al. Attenuation of Ras signalling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003; 63: 1975-1980.